WASHINGTON, Sept. 19, 2018 /PRNewswire/ -- A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be very useful for private payers' medicine coverage decisions.
The whitepaper, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA), identifies several problems in applying ICER's reports to inform coverage decisions by private payers, including:
Not only do ICER's assessments fail to align with the needs of private payer decision making, but research released earlier this year found that if these assessments were used to determine medicine coverage, it could significantly limit patients' access to life-changing innovative therapies.
Read the full Milliman report to learn more about the disconnect between U.S. private payer needs and ICER's CEAs.
This post originally appeared at: https://catalyst.phrma.org/new-whitepaper-identifies-reasons-why-icers-cost-effectiveness-analyses-are-not-useful-for-payers
SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)
To read more Press Release articles, click here.